



Prometheus Biosciences, Inc. (RXDX US)

COMPANY DESCRIPTION

Prometheus Biosciences is a biotechnology company from San Diego, California. The company was initially founded in 2016 as Precision IBD and is based on research by Cedars Sinai Medical Center inflammatory bowel disease (IBD) specialist Dr. Stephan Targan. The company focuses on treatments for autoimmune diseases. 🚀

AREA OF RESEARCH

The company research focuses primarily on monoclonal antibody (mAb) therapies, for which they have two main programs. **PRA023** is currently in Phase 2 clinical trials for the treatment of Ulcerative Colitis, Crohn's Disease and Lung Sclerosis. Their second-most advanced program, **PRA052** is about to go into Phase 1 clinical trial in Q4 2022 and focuses on Ulcerative Colitis. Both drugs aim to block natural


compounds associated with inflammation. Furthermore, the firm aims to leverage a database of samples from 20,000 patients (**Prometheus360**) to identify novel therapeutic targets for a precision medicine approach.

IPO HISTORY


On **03/12/2021**, Prometheus Biosciences began trading on the Nasdaq Global Market under the ticker **RXDX US**. The IPO was managed by SVB Leerlink, Credit Suisse, Guggenheim and Stifel. The company raised \$218.50m, offering 10 million shares at \$19/share. The shares opened at \$24.95 and closed at \$25.29 on the first day (▲33.11%). 🚀

Prometheus Biosciences was included in the IPOX® 100 U.S. Index (ETF: FFX US, FFX LN) on 09/19/2022 and currently weighs ca. 0.12% of the portfolio. 🚀

HISTORICAL PERFORMANCE




GROWTH OUTLOOK



Prometheus Biosciences therapeutic pipeline

Program	Indication	Discovery	Validation	IND-enabling	Phase 1	Phase 2	Phase 3
PRA023 Anti-IL1A mAb	Ulcerative Colitis						
	Crohn's Disease						
	SSc-ILD						
PRA052*	Ulcerative Colitis						
PR300	GPCR modulator small molecule						
PR1100	Anti-cytokine receptor mAb						
PR2100	Anti-inflammatory cytokine mAb						
Undisclosed Preclinical Targets	Multiple						



PrometheusID **PrometheusIQ**

INDUSTRY COMPARISON

COMPANY	STOCK SYMBOL	IPO DATE	INITIAL RETURN	OFFER TO DATE (TR)	2022 YTD	BETA TO BENCHMARK	REVENUE (Millions)	DILUTED EPS	Sales Growth YoY	P/S Ratio
Prometheus Biosciences	RXDX US	03/12/2021	33.11%	170.74%	30.10%	N/A	\$3.1	-\$2.88	155%	277.5x
ventyX biosciences	VTYX US	10/20/2021	31.38%	108.56%	68.03%	N/A	\$0	-\$6.53	0%	N/A
Protagonist Therapeutics	PTGX US	08/10/2016	-2.50%	-28.04%	-74.75%	1.55	\$27.4	-\$2.71	-4%	9.2x
Third Harmonic Bio	THRD US	09/14/2022	15.76%	32.11%	N/A	N/A	\$0	N/A	0%	N/A